Subsets of exhausted CD8

Animals Antibodies, Blocking / immunology CD8-Positive T-Lymphocytes / drug effects Cell Line, Tumor Female Humans Lymphocyte Subsets / drug effects Lymphocytes, Tumor-Infiltrating / drug effects Lymphocytic Choriomeningitis / immunology Lymphocytic choriomeningitis virus / drug effects Melanoma, Experimental / immunology Mice, Congenic Mice, Inbred C57BL Programmed Cell Death 1 Receptor / antagonists & inhibitors

Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
03 2019
Historique:
received: 12 06 2018
accepted: 03 01 2019
entrez: 20 2 2019
pubmed: 20 2 2019
medline: 2 5 2019
Statut: ppublish

Résumé

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8

Identifiants

DOI: 10.1038/s41590-019-0312-6 PMID: 30778252 PMC: PMC6673650
pubmed: 30778252
doi: 10.1038/s41590-019-0312-6
pii: 10.1038/s41590-019-0312-6
pmc: PMC6673650
mid: NIHMS1026478
doi:

Substances chimiques

Antibodies, Blocking 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-336

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI056299
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007627
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007753
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI130408
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009172
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI133524
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI115712
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA207021
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

J Immunol. 1999 Jun 1;162(11):6442-50
pubmed: 10352258
Cancer Res. 1975 Jan;35(1):218-24
pubmed: 1109790
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7731-6
pubmed: 12796513
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Curr Protoc Microbiol. 2008 Feb;Chapter 15:Unit 15A.1
pubmed: 18770534
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016-21
pubmed: 18809920
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
J Immunol. 2011 Dec 1;187(11):5964-73
pubmed: 22039299
Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Pigment Cell Melanoma Res. 2014 May;27(3):495-501
pubmed: 24460976
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Immunity. 2015 Feb 17;42(2):265-278
pubmed: 25680272
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923
Cell. 2015 Sep 10;162(6):1217-28
pubmed: 26321681
Nat Immunol. 2016 Oct;17(10):1187-96
pubmed: 27487330
Nature. 2016 Aug 2;537(7620):412-428
pubmed: 27501245
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
BMC Bioinformatics. 2016 Aug 23;17(1):315
pubmed: 27553427
Cell. 2016 Sep 8;166(6):1500-1511.e9
pubmed: 27610572
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Science. 2016 Dec 2;354(6316):1165-1169
pubmed: 27789799
Sci Immunol. 2016 Dec 23;1(6):null
pubmed: 28018990
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2776-E2785
pubmed: 28283662
Nature. 2017 May 25;545(7655):452-456
pubmed: 28514453
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Cancer Immunol Res. 2018 Jan;6(1):14-24
pubmed: 29097422
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2162-2167
pubmed: 29440380
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
J Exp Med. 2018 Oct 1;215(10):2520-2535
pubmed: 30154266
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Nature. 1993 Apr 22;362(6422):758-61
pubmed: 8469287
J Exp Med. 1998 May 4;187(9):1383-93
pubmed: 9565631
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Science. 1999 Feb 5;283(5403):857-60
pubmed: 9933172

Auteurs

Brian C Miller (BC)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-5931-4184

Debattama R Sen (DR)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-0947-8284

Rose Al Abosy (R)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
ORCID: 0000-0001-5400-1306

Kevin Bi (K)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Yamini V Virkud (YV)

Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.

Martin W LaFleur (MW)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-5017-774X

Kathleen B Yates (KB)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Ana Lako (A)

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Kristen Felt (K)

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Girish S Naik (GS)

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Michael Manos (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Evisa Gjini (E)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Juhi R Kuchroo (JR)

Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.

Jeffrey J Ishizuka (JJ)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Jenna L Collier (JL)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0002-4071-4986

Gabriel K Griffin (GK)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Seth Maleri (S)

Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.

Dawn E Comstock (DE)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.

Sarah A Weiss (SA)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.

Flavian D Brown (FD)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.

Arpit Panda (A)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Margaret D Zimmer (MD)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Robert T Manguso (RT)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

F Stephen Hodi (FS)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Scott J Rodig (SJ)

Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Arlene H Sharpe (AH)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.

W Nicholas Haining (WN)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. wnhaining@gmail.com.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. wnhaining@gmail.com.
Division of Medical Sciences, Harvard Medical School, Boston, MA, USA. wnhaining@gmail.com.
ORCID: 0000-0001-7871-3762

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Subsets of exhausted CD8
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bloquants › Subsets of exhausted CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Subsets of exhausted CD8
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Subsets of exhausted CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Subsets of exhausted CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Sous-populations de lymphocytes › Subsets of exhausted CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Subsets of exhausted CD8
questionsmedicales.fr › Maladies du système nerveux › Méningite › Méningite virale › Chorioméningite lymphocytaire › Subsets of exhausted CD8
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Arenaviridae › Arenavirus › Arénavirus de l'Ancien Monde › Virus de la chorioméningite lymphocytaire › Subsets of exhausted CD8
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Tumeurs expérimentales › Mélanome expérimental › Subsets of exhausted CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris congéniques › Subsets of exhausted CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Subsets of exhausted CD8
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Subsets of exhausted CD8